Author

Laxmikant Wali

Institution: Sarepta Therapeutics (United States)

Observed institution: Sarepta Therapeutics (United States)

ORCID: 0000-0001-9086-0626

Observed ORCID: 0000-0001-9086-0626

OpenAlex ID: A5074527252

Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2

2022 · Laxmikant Wali, Michael Karbiener, et al. · Journal of Virus Eradication · 11

Nebulized 2-deoxylated glucose analogues inhibit respiratory viral infection in advanced in vitro airway models

2025 · Sarah K. Wideman, Laxmikant Wali, et al. · Scientific Reports · 2

One drug to rule them all: Targeting host cell metabolic pathway to combat respiratory infections

2022 · Laxmikant Wali, Michael Karbiener, et al.

Works count: 3

Citation count: 13

H-index: 2

I10-index: 1